Salient Pharma ApS: Financial statements 2019
CVR: 36900709
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -729,822 and a net result of DKK -2,359,834 compared with DKK -710,176 the year before. Equity in the 2019 report amounted to DKK 409,647. The solvency ratio was 70.8%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -729,822
- Profit/Loss
- DKK -2,359,834
- Equity
- DKK 409,647
- Total Assets
- DKK 578,899
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -730 t. | -2.4 mio. | 410 t. | 1 |
| 2018 | - | -838 t. | -710 t. | 2.8 mio. | - |
| 2017 | - | -1.2 mio. | -971 t. | -1.8 mio. | - |
| 2016 | - | -955 t. | -772 t. | -847 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Salient Pharma ApS has published its annual report for 2018. Gross profit came to DKK -837,788, and the net result was DKK -710,176.
About Salient Pharma ApS
Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The board consists of Helle Bøwadt, Søren Wang Petersen and Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity in the 2025 report amounted to DKK -1,344,010.